Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rafutidine
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rafutidine is a second-generation histamine H2-receptor antagonist (H2RA) characterized by its potent, long-acting inhibition of gastric acid secretion and unique gastroprotective properties. Unlike traditional H2RAs, rafutidine stimulates capsaicin-sensitive sensory nerves in the gastric mucosa, leading to the release of calcitonin gene-related peptide (CGRP) and increased nitric oxide production, which enhances mucosal blood flow and promotes healing. Originally developed by Fujisawa Pharmaceutical (now Astellas Pharma) and Taiho Pharmaceutical, it is approved for the treatment of gastric and duodenal ulcers, reflux esophagitis, and gastritis. In South Korea, companies like Kwangdong Pharm market generic versions of the drug.
- Brand names
- StogarProtecadin
- Other names
- rafutidinerafutidina
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on rafutidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rafutidine.